Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity

Helicobacter

Volumn 20, Issue 6, 2015, Pages 405-409

  Polyzos, Stergios A ^a   Kountouras, Jannis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Helicobacter pylori; Homeostasis model of assessment; Insulin resistance; Metabolic syndrome

Indexed keywords

AMOXICILLIN; C REACTIVE PROTEIN; CLARITHROMYCIN; FIBRINOGEN; GAMMA INTERFERON; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 203; OMEPRAZOLE; PROSTAGLANDIN; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA C 13;

ATHEROSCLEROSIS; ATROPHIC GASTRITIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE ERADICATION; DYSBIOSIS; DYSLIPIDEMIA; EDITORIAL; ENDOSCOPY; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; GOLD STANDARD; HEART INFARCTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LEUKOCYTE AGGREGATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RAPID UREASE TEST; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN; COMPLICATION; PATHOGENICITY; PATHOLOGY;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METABOLIC SYNDROME X;

EID: 84955213674     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12228     Document Type: Editorial

References (26)

1. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011;16:79-88.
2. Polyzos SA, Kountouras J, Papatheodorou A, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013;62:121-6.
3. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease. Med Hypotheses 2014;82:795.
4. Romiopoulos I, Kountouras J, Polyzos SA, et al. Helicobacter pylori-related metabolic syndrome might justify earlier colorectal cancer screening. Gastrointest Endosc 2014;80:188-9.
5. Calvet X, Ramirez Lazaro MJ, Lehours P, Megraud F. Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter 2013;18(Suppl 1):5-11.
6. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter 2014;19(Suppl 1):1-5.
7. McCullough AJ. Epidemiology of the metabolic syndrome in the USA. J Dig Dis 2011;12:333-40.
8. Banic M, Franceschi F, Babic Z, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2012;17(Suppl 1):49-55.
9. Chen TP, Hung HF, Chen MK, et al. Helicobacter pylori infection is positively associated with metabolic syndrome in Taiwanese adults: a cross-sectional study. Helicobacter 2015; doi:10.1111/hel.12190.
10. Megraud F, Bessede E, Lehours P. Diagnosis of Helicobacter pylori infection. Helicobacter 2014;19(Suppl 1):6-10.
11. Nam SY, Ryu KH, Park BJ, Park S. Effects of Helicobacter pylori infection and its eradication on lipid profiles and cardiovascular diseases. Helicobacter 2014; doi:10.1111/hel.12182.
12. Liu J, Wang F, Shi S. Helicobacter pylori infection increase the risk of myocardial infarction: a meta-analysis of 26 studies involving more than 20, 000 participants. Helicobacter 2014; doi:10.1111/hel.12188.
13. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32.
14. Zhou X, Liu W, Gu M, Zhou H, Zhang G. Helicobacter pylori infection causes hepatic insulin resistance by the c-Jun/miR-203/SOCS3 signaling pathway. J Gastroenterol 2015; doi:10.1007/s00535-015-1051-6.
15. Carabotti M, D'Ercole C, Iossa A, Corazziari E, Silecchia G, Severi C. Helicobacter pylori infection in obesity and its clinical outcome after bariatric surgery. World J Gastroenterol 2014;20:647-53.
16. Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998;316:1130-2.
17. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009;72:299-314.
18. Ericksen RE, Rose S, Westphalen CB, et al. Obesity accelerates Helicobacter felis-induced gastric carcinogenesis by enhancing immature myeloid cell trafficking and TH17 response. Gut 2014;63:385-94.
19. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719-31.
20. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Helicobacter pylori and insulin resistance association: not just a myth, not yet a fact. Saudi J Gastroenterol 2011;17:425-6.
21. Gunji T, Matsuhashi N, Sato H, et al. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter 2009;14:144-50.
22. Naja F, Nasreddine L, Hwalla N, et al. Association of H. pylori infection with insulin resistance and metabolic syndrome among lebanese adults. Helicobacter 2012;17:444-51.
23. Jeon CY, Haan MN, Cheng C, et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012;35:520-5.
24. Lopetuso LR, Scaldaferri F, Franceschi F, Gasbarrini A. The gastrointestinal microbiome - functional interference between stomach and intestine. Best Pract Res Clin Gastroenterol 2014;28:995-1002.
25. Caricilli AM, Saad MJ. Gut microbiota composition and its effects on obesity and insulin resistance. Curr Opin Clin Nutr Metab Care 2014;17:312-8.
26. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 2012;46:272-84.